Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (NCT02665065)

🧪 Interventions in This Study

• Iomab-B (DRUG)
• Conventional Care (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• Banner MD Anderson Cancer Center — Gilbert, Arizona
• Yale Cancer Center — New Haven, Connecticut
• Georgetown University Medical Center — Washington D.C., District of Columbia
• Mayo Clinic — Jacksonville, Florida
• Loyola University Medical Center — Maywood, Illinois
• University of Iowa — Iowa City, Iowa
• The University of Kansas Cancer Center — Westwood, Kansas
• Mayo Clinic — Rochester, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• University of Nebraska Medical Center — Omaha, Nebraska
• Roswell Park Cancer Institute — Buffalo, New York
• Weill Cornell Medicine — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Stony Brook University — Stony Brook, New York
• University of North Carolina Hospital — Chapel Hill, North Carolina
• University Hospital of Cleveland Seidman Cancer Center — Cleveland, Ohio
• The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
• Oregon Health & Science University — Portland, Oregon
• Baylor Charles A. Sammons Cancer Center — Dallas, Texas
• MD Anderson Cancer Center — Houston, Texas
• Fred Hutchinson Cancer Research Center — Seattle, Washington
• Medical College of Wisconsin — Milwaukee, Wisconsin
• University of Ottawa — Ottawa, Ontario
• Princess Margaret Cancer Centre — Toronto, Ontario

📞 Contact the Study Coordinator

Phone: (877) 632-6789

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukemia

• PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
• Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
• A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
• A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California

Explore by condition: All Acute Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.